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INTRODUCTION
Charcot-Marie-Tooth (CMT) disease is a clinically and genet-
ically heterogeneous group of hereditary peripheral neuropa-
thies. The clinical characteristics of the disease include distal
symmetric muscle weakness, atrophy, bilateral pes cavus, and
diminished or absent deep tendon reflexes. Peripheral nerve
conduction velocities are often severely reduced. In hereditary
neuropathy with liability to pressure palsy (HNPP), recur-
rent peripheral nerve palsies (e.g., ulnar nerve, median nerve,
and peroneal nerve palsies) occur because of minor compres-
sion trauma, whereas foot deformity is less frequently observed
than it is in CMT. Nerve conduction velocities are significant-
ly reduced at compression sites of peripheral nerves.
Charcot-Marie-Tooth disease type 1A (CMT1A) is the most
common form of CMT (1, 2). About 70% of CMT1A cases
are caused by a dominantly inherited 1.5-Mb duplication at
17p11.2-12, encompassing the peripheral myelin protein-22
gene (PMP22) (3-5). In contrast, deletion of the PMP22 char-
acteristically results in HNPP. Point mutation in the PMP22
may result in CMT1A or HNPP. Thus heterozygous carriers
of the deletion (HNPP) or duplication (CMT1A) have one or
three copies of the PMP22, respectively. For molecular diag-
nosis of duplication or deletion of the PMP22, several approach-
es including Southern blot analysis (6), fluorescence in situ
hybridization (FISH) (7, 8), pulsed-field gel electrophoresis
(PFGE) (4, 9), polymorphic short tandem repeats (STR) anal-
ysis (7, 10, 11), and endpoint quantitative PCR (12, 13) are
available.
STR-PCR methods have been widely used because of its
advantages in cost, labor, amount of DNA sample required,
and turnaround time. However, there is a limitation in sen-
sitivity (14), and DNA samples of parents are required in mark-
er typing. Detection of the PMP22 duplication and deletion
by real-time quantitative PCR using TaqMan probes has been
reported (15-17). The method is fast, allowing 13 patients
to be diagnosed in 2 hr. However, specific probes are required
in real-time quantitative PCR using TaqMan probes, but not
in real-time quantitative PCR using SYBR Green I. Real-
time quantitative PCR using SYBR Green I has been used
previously for quantification of specific human genes (18, 19),
as well as detection and quantification of DNA of virus, bac-
teria, and fungus (20-23). However, there was no study on
detecting the PMP22 duplication and deletion by real-time
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Rapid Detection of Duplication/Deletion of the PMP22 Gene in
Patients with Charcot-Marie-Tooth Disease Type 1A and Hereditary
Neuropathy with Liability to Pressure Palsy by Real-time Quantitative
PCR using SYBR Green I Dye
Mutations and altered gene dosage of the peripheral myelin protein (PMP22) gene
in chromosome 17p11.2-12 are the main causes for hereditary neuropathies, ac-
counting for approximately 70% of all cases. Patients with duplication of the PMP22
develop Charcot-Marie-Tooth disease type 1A (CMT1A) and deletion of one PMP22
allele leads to hereditary neuropathy with liability to pressure palsy (HNPP). Twenty
patients with CMT1A, 17 patients with HNPP, and 18 normal family members and
28 normal controls were studied by real-time quantitative PCR using SYBR Green
I on the ABI 7700 Sequence Detection System. The copy number of the PMP22
gene was determined by the comparative threshold cycle method and the albumin
was used as a reference gene. The PMP22 duplication ratio ranged from 1.45 to
2.06 and the PMP22 deletion ratio ranged from 0.42 to 0.64. The PMP22 ratio in
normal controls, including normal family members, ranged from 0.85 to 1.26. No
overlap was found between patients with CMT1A or patients with HNPP and normal
controls. This method is fast, highly sensitive, specific, and reproducible in detect-
ing PMP22 duplication and deletion in CMT1A and HNPP patients, respectively.
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quantitative PCR using SYBR Green I dye. In this study, we
used real-time quantitative PCR using SYBR Green I to detect
the PMP22 duplication and deletion. Using a comparative
Ct (threshold cycle) method, the relative gene copy number
was quantified (16, 17).
MATERIALS AND METHODS
Subjects
The study subjects were 20 patients with CMT1A, 17 pa-
tients with HNPP, 18 asymptomatic normal family members,
and 28 normal unrelated controls. Clinical and neurophysi-
ological examinations were performed on all patients. Dupli-
cation or deletion of the PMP22 gene in CMT1A or HNPP
patients was diagnosed previously by short tandem repeats
(STR) analysis with three polymorphic markers, D17S122,
D17S162, and D17S261. Informed consents were obtained
from all individuals participating in this study.
DNA extraction
Genomic DNA was extracted from leukocytes of EDTA-
treated blood using the QIAamp DNA blood kit (QIAGEN).
The concentration and purity of the preparations were deter-
mined by measuring the absorbance at 260 and 280 nm.
DNAs were diluted in distilled water to a concentration of
1.25 ng/ L and stored at -20℃ until use.
Primer design and real-time quantitative PCR
The primer sequences were as follows; PMP22 exon 3 for-
ward primer, 5′-TCTGTCCAGGCCACCATGA-3′; PMP22
exon 3 reverse primer, 5′-GAAGAGTTGGCAGAAGAA-
CAGGA-3′; human serum albumin exon 12 forward primer,
5′-TGTTGCATGAGAAAACGCCA-3′; human serum albu-
min exon 12 reverse primer, 5′-GTCGCCTGTTCACCAA-
GGAT-3′. A 3-by-3-primer matrix (combinations of 1 M,
5 M, and 10 M of each forward and reverse primers) was
analyzed to determine the optimal concentrations of both
forward and reverse primers. The minimum primer concen-
trations that resulted in the lowest Ct-value (threshold cycle)
and highest fluorescent signal (△Rn), while minimizing non-
specific amplification, were chosen as an optimal pair. The
amplifications were carried out in a 96-well plate in a 20 L
reaction volume containing 10 L SYBR Green PCR Mas-
ter Mix (Applied Biosystems, Foster City, Califonia, U.S.A.),
5 M (1 L) forward primer, 5 M (1 L) reverse primer, and
10 ng (8 L) of genomic DNA. In each assay, 2 or more nor-
mal controls and no-template control were included. Each
sample was run in triplicate for both PMP22 and albumin. The
96-well sample tray was centrifuged briefly at 3,000 rpm for
2 min. PCR reactions were run in the ABI PRISM 7700 Se-
quence Detection System (Applied Biosystems). Preincubation
was performed for 10 min at 95℃ to denature the target DNA
and activate AmpliTaq Gold DNA Polymerase. DNA was
amplified for 40 cycles of 15 sec at 95℃ and 1 min at 65℃.
The annealing and extension temperatures were optimized
for specificity of the PCR product. The fluorescence signal
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Fig. 1. Amplification plots of peripheral myelin protein 22 (PMP22)
and albumin, all in triplicates, of: (A) normal control (△△Ct ratio
0.98, SD PMP22 0.06, SD albumin 0.19); (B) CMT1A patient with
PMP22 duplication (△△Ct ratio 1.82, SD PMP22 0.06, SD albumin
0.07); (C) HNPP patient with PMP22 deletion (△△Ct ratio 0.51, SD
PMP22 0.07, SD albumin 0.05).
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was measured at the end of the elongation phase. We used
MicroAmp Optical Caps and MicroAmp Optical 96-Well
Reaction Plates (Applied Biosystems).
Data analysis
The data was analyzed by using the ABI PRISM Sequence
Detection System and Microsoft Excel. The relative gene copy
number was quantified by the comparative Ct method (16,
17). Amplicons were run as triplicates in separate tubes to
permit quantification of the PMP22 gene normalized to albu-
min, an endogenous gene, as a control. By using a calibrator
sample of normal control DNA, the gene copy number of
unknown samples was estimated. The patients, families, and
normal controls were analyzed in parallel with the calibrator
sample on each assay plate. The threshold cycle number (Ct)
was determined for all PCR reactions. The Ct parameter rep-
resents the cycle number (△Rn) at which the amplification
plot, representing the fluorescence emission of the reporter
dye, passed a fixed threshold. The threshold was automatical-
ly set at 10 standard deviations (SD) above the mean baseline
emission. However, the threshold was manually adjusted with-
in the logarithmic curve, above the background level (calcu-
lated from cycles 3-15) and below the plateau phase. The same
threshold and baseline were set for all samples including the
calibrator samples. Using the comparative Ct method, the
starting copy number of the samples was determined: △Ct
represents the mean Ct value of each sample and was calcu-
lated for PMP22 and albumin. The starting copy number of
the unknown samples was determined relative to the known
copy number of the calibrator sample using the following for-
mula: DDCt=[△Ct albumin (calibrator sample)-△Ct PMP22
(calibrator sample)]-[△Ct albumin (unknown sample)-△Ct
PMP22 (unknown sample)]. The relative gene copy number
was calculated by the expression 2-△△Ct. This formula was based
on the assumption that the rate of Ct change versus the rate
of target DNA copy change was identical for both the PMP22
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Samples
△△Ct ratio
Mean Range SD
Normal (n=46) 1.09 0.85-1.26 0.09
CMT1A (n=20) 1.66 1.45-2.06 0.16
HNPP (n=17) 0.53 0.42-0.64 0.06
Table 1. PMP22 gene copy number (relative ratio) detected by
real-time quantitative PCR using SYBR Green I dye
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Fig. 2. A CMT1A family (patient, symptomatic mother and healthy
father) (A) STR analysis: the patient and mother showed PMP22
duplication in marker D17S122; (B-D) Amplification plots of PMP22
and albumin of the patient (B△△Ct ratio 1.51), mother (C△△Ct
ratio 1.55), and father (D△△Ct ratio 1.03). 
Lane 1: Patient, 2: Mother, 3: Father.
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gene of interest and albumin. Using this method, a △△Ct ratio
is expected to be about 1 in normal controls, about 0.5 in pa-
tients with HNPP and about 1.5 in patients with CMT1A.
RESULTS
The triplicate runs of PMP22 and albumin showed almost
complete overlap of parallel amplification plots. For all sam-
ples the SD of Ct values was very low (mean, 0.09; range,
0.01-0.33). The PCR amplification plots of a normal control
sample (Fig. 1A) showed a slightly increased but nearly iden-
tical Ct value of PMP22 triplicates, compared with that of
albumin. In samples positive for the PMP22 duplication
(CMT1A), the Ct value of PMP22 showed a decrease of about
0.5, compared with that of albumin (Fig. 1B), whereas, in
samples positive for the PMP22 deletion (HNPP), the Ct
value of PMP22 showed an increase of about 1.2, compared
with that of albumin (Fig. 1C).
Table 1 shows the △△Ct ratios [2-(△△Ct)] in three groups.
The mean △△Ct ratio in normal controls, including asymp-
tomatic normal family members, was 1.09 (range, 0.85-1.26).
The mean △△Ct ratio in CMT1A patients was 1.66 (range,
1.45-2.06). The mean △△Ct ratio in HNPP patients was
0.53 (range, 0.42-0.64). Real-time quantitative PCR analy-
sis results of one CMT1A and HNPP case confirmed by STR
analysis showed correct determination of the PMP22 gene
copy number (Fig. 2 and 3).
DISCUSSION
For detection of duplication and deletion of PMP22 gene,
Southern blot analysis or STR marker typing have been wide-
ly used. However, these methods have several limitations.
Southern blot analysis is not only time-consuming work but
also requires large amount of patient’s DNA. Although for
STR marker typing, small DNA samples are sufficient for the
procedure but DNA samples of parents are necessary for inter-
pretation.
The recently developed real-time quantitative PCR is fast
and precise, and avoids the use of hazardous radioisotopes (15-
17, 24). In real-time quantitative PCR assay, the initial copy
number of the target template is determined by analyzing the
cycle-to-cycle change in fluorescence signal as a result of the
amplification of the template during PCR. The fewer cycles
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Fig. 3. A HNPP family (patient, symptomatic father and healthy mo-
ther) (A) STR analysis: the patient showed PMP22 deletion in mark-
er D17S122 and D17S261; (B-D) Amplification plots of PMP22 and
albumin of the patient (B △△Ct ratio 0.51), father (C △△Ct ratio
0.50), and mother (D△△Ct ratio 1.06).
Lane 1: Patient, 2: Mother, 3: Father.
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it takes to reach a detectable level of fluorescence, the greater
the initial copy number. Detection of the PMP22 duplication
and deletion by real-time quantitative PCR (15-17) are fast
and sensitive. The method takes only 2 hr and does not require
post-PCR processing. In addition, DNA samples of parents
are not required. Real-time quantitative PCR using SYBR
Green I dye will be more convenient and cost effective than
using expensive TaqMan probes. We now established real-time
quantitative PCR using SYBR Green I dye for fast, cheap, and
reliable detection of the gene copy number of the PMP22 gene.
We studied 20 CMT1A and 17 HNPP patients by real-time
quantitative PCR using SYBR Green I dye, which confirmed
previously for duplication or deletion of the PMP22 gene by
STR analysis. The PCR amplification plots of the PMP22
gene of normal control samples showed slightly increased but
nearly identical Ct values compared with albumin. By the
comparative Ct method, the relative PMP22 gene copy num-
ber was determined. The lower and upper limits of PMP22
duplication ratio in CMT1A patients were 1.45 and 2.06,
respectively. This result indicated that the PMP22 gene copy
number in CMT1A patients was three or four. The lower and
upper limits of PMP22 deletion ratio in HNPP patients were
0.42 and 0.64, respectively. This result indicated that the
PMP22 gene copy number in HNPP patients was one. In 28
normal controls and 18 normal family members, the PMP22
ratio ranged from 0.85 to 1.26. No overlap was observed
between CMT1A or HNPP patients and normal controls.
In conclusion, real-time quantitative PCR using SYBR Green
I is highly sensitive, specific, and reproducible in detecting PMP22
duplication and deletion in patients with CMT1A and HNPP.
This method will be very helpful for the diagnosis of patients
with CMT1A/HNPP as well as genetic counseling for their
family.
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